Trial NCT03773302

View at ClinicalTrials.gov 
Org. Study IDs: QBGJ398-301
Secondary IDs: 2018-004004-19

Last trial update was posted on 2023-04-03

MeSH Interventions

Gemcitabine Infigratinib

MeSH Conditions

Cholangiocarcinoma

Other Conditions

Advanced Cholangiocarcinoma FGFR2 Gene Mutation

Stopping Reasons

The sponsor has decided to close the study due to the discontinuation of infigratinib development in oncology within the sponsor's territory. The discontinuation of the study was not due to safety issues.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID